Homburger advised VectivBio on up to USD 75 m loan facility with Kreos Capital

On March 30, 2022, VectivBio, a clinical-stage biotechnology company developing transformational medicines for patients with serious rare diseases, announced that it has, inter alia, entered into a loan agreement with Kreos Capital, a leading global growth lender to life sciences and healthcare companies, granting VectivBio access to a up to USD 75 m flexible loan facility.

Homburger advised VectivBio with regard to all Swiss legal and tax aspects of the financing transaction.

The Homburger team included partner Andreas Müller (Corporate / M&A, Life Sciences), lead associate Stefan Bindschedler (Financing and Investment Products), partners Jürg Frick (Financing and Investment Products), Stefan Oesterhelt (Tax) and Luca Dal Molin (IP / IT) as well as associates Kevin Hubacher, Angela Oppliger (both Corporate / M&A) and Kevin Müller (Tax).